A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

University of North Carolina (UNC)

Status: Active, not recruiting

Conditions: Focal Epilepsy With Secondary Generalization; Partial Seizures With Secondary Generalization

Treatments: Device: High Intensity Focused Ultrasound

Study type: Interventional

Funder types: Other

Identifiers

NCT03417297

22-0350

Details and patient eligibility

About

The purpose of this study is to assess the safety and feasibility of unilateral focused ultrasound thalamotomy in adults with focal onset epilepsy whose medicines are not working well. The ExAblate (ExAblate) transcranial system is the name of the device that will be used to create and send ultrasound waves through the scalp and skull precisely to a small structure located in the center of the brain. This structure is known as the "Anterior Nucleus", and is an important region in the brain that may cause seizures. Safety will be measured by recording and analyzing the frequency of side effects throughout participation. Feasibility will be measured by the ability to create a lesion in the anterior nucleus.

Full description

This is an open-label prospective intervention study. Ten (10) adults with refractory, focal epilepsy with secondary generalization and able to provide informed consent will undergo focused ultrasound (FUS) thalamotomy. In addition to the diagnosis of medically refractory epilepsy, these patients will need to meet protocol specific inclusion and exclusion criteria. These adults will be screened from the patients being cared for by the epilepsy program at the University of North Carolina at Chapel Hill or referred from elsewhere for enrollment in the study. Initially, 3 participants will be enrolled and followed for 3 months to assess the safety of study intervention. Pending review by the Data and Safety Monitoring Committee (DSMC) and the US Food and Drug Administration (FDA), additional subjects will be enrolled.

This pilot study is being conducted to test the feasibility of this device in order to confirm the design and operating specifications of the device including the ability to identify and accurately ablate the target focus within the Anterior Nucleus.

Safety will be assessed by the frequency of side effects, e.g., new onset of neurological deficits, performance deterioration on neuropsychological testing. Feasibility is defined as the ability to create the desired lesion within the anterior nucleus.

Seizure frequency data will be collected by seizure questionnaire. Quality of life will be measured by the Quality of Life in Epilepsy Inventory (QOLIE-31). Imaging analysis will include a comparison of pre- and post-intervention imaging to identify brain networks associated with clinical outcomes and determine changes in resting-state functional connectivity (assessed by fMRI), as well as in structural (assessed by volumetric T1 and T2 weighted imaging) and microstructural (assessed by diffusion tensor imaging) brain anatomy.

Subject satisfaction with FUS thalamotomy will be assessed by the Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19).

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Medically refractory epilepsy (≥2 antiepileptic drug failures) deemed disabling by the patient and study investigators.

• Focal seizures with secondary generalization; with or without primary generalized seizures.

• ≥ 3 seizures/month on average based on seizure diary of patient's preferred format during the three months prior to enrollment.

• Stable prescribed epilepsy medication dosages, including stopping or starting medication, for 3 months before enrollment.

• Anterior Nucleus (AN) identifiable on MRI (structural T1 and T2 images).

• Willing to maintain seizure diary (3 months before & 3 months after the study treatment).

• Involved caregiver such as a spouse, family member, or family friend willing to provide reliable care during the study participation.

• Ability to provide written informed consent to participate.

• Previous seizure work-up to include:

  1. Home EEG, Epilepsy Monitoring Unit (EMU) video EEG, or intracranial EEG.
  2. Baseline neuropsychological assessment, which includes the Wechsler Advanced Clinical Solutions - Test of Premorbid Functioning (TOPF). Participants obtaining an Intelligence Quotient (IQ) score of ≥70 on the TOPF will be included.
  3. High-definition MRI imaging/Position emission tomography (PET) imaging.

Exclusion criteria

• Have on average less than 3 seizures a month.
• Have an indwelling vagal nerve stimulator.
• Have severe untreated neuropsychiatric disorders (e.g., untreated depression or behavioral problems).
• History of drug or alcohol abuse in the last 12 months.
• Presence of primary generalized epilepsy (e.g., Lennox Gastaut, drop attacks).
• Presence of post-infectious epilepsy (i.e., epilepsy from post-herpetic encephalitis).
• Previous corpus callosotomy (surgery to cut the fibers, called the corpus callosum, that separate each half of the brain).
• Significant structural brain abnormalities.
• Unable or unwilling to maintain your current anti-seizure drug dosage for 3 months post-treatment.
• Pregnant or not practicing birth control methods.
• History of claustrophobia (fear of closed spaces).
• Presence of an MRI contraindicated implanted metal or medical device (e.g., pacemaker, metallic joints, or insulin pump).
• Uncontrolled hypertension or other comorbid conditions (e.g., uncontrolled heart or lung disease).
• Skull Density Ratio (SDR) <0.4.
• IQ score of <70 on the Wechsler Advanced Clinical Solutions - Test of Premorbid Functioning (TOPF), a measure conducted as part of baseline neuropsychological assessment.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

high intensity focused ultrasound

Experimental group

Description:

Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then additional subjects will be enrolled.

Treatment:

Device: High Intensity Focused Ultrasound